Curing hematologic cancers with precision medicine and minimal toxicity has been a multigeneration challenge and a highly prioritized work for our group at Yale. Through continual engagement with patients and their families, educational meetings and well informed decision making sessions, we help our patients navigate the field of transplantation and cellular therapy. Our multidisciplinary team while trying to harness the curative promise of cellular immunotherapy also has special focus to enhance its safety and provide long term supervision for cancer survivors. We strongly encourage our patients to learn the strengths and limitations of the existing standard of care, the knowledge of which could be applied to personalize treatment plans and foster research environment to advance the broader field.
| Award | Date |
|---|---|
| American Society of Hematlogy Abstract Achievement Award | 2017 |
| Academy of Clinical Laboratory Physicians and Scientists-Paul E. Strandjord Young Investigator Award | 2016 |
| American Association of Blood Banks-Fenwal Scholarship | 2015 |
| Best Resident of the Month | 2010 |
| First Prize, Annual Research Day, Drexel University Collge of Medicine | 2009 |
| Organization | Role | Date |
|---|---|---|
| YCC Data Safety Monitoring Committee | Member | 2019 - Present |
| American Society for Blood and Marrow Transplantation | Member | 2019 - Present |
| Yale New Haven Hospital Transfusion Committee | Member | 2018 |
| Yale Stem Cell Transplant QI Committee | Member | 2018 - Present |
| American Association of Blood Banks | Member | 2014 - 2016 |
| Journal of Hematology & Oncology, Transfusion, Frontiers in Immunology | Ad-hoc reviewer | 2014 - 2015 |
| Journal of American Medical Association | Ad-hoc reviewer | 2011 - 2012 |
| American Society of Oncology | Member | 2011 - Present |
| American Society of Hematology | Member | 2011 - Present |